Two distinctive ccRCC subgroups were uncovered and compared at multiomics level and targeting matrix remodeling associated 5 (MXRA5) could be treated as an effective approach to suppress ccRCC progression. This evidence concerns the gene MXRA5 and nonpapillary renal cell carcinoma.